AC Immune Regains Full Rights to Alzheimer's Drugs Crenezumab, Semorinemab
Ticker: ACIU · Form: 6-K · Filed: Jan 22, 2024 · CIK: 1651625
| Field | Detail |
|---|---|
| Company | Ac Immune SA (ACIU) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: collaboration-termination, drug-rights, biotech, alzheimers
TL;DR
**AC Immune just got back full control of two major Alzheimer's drugs, crenezumab and semorinemab, from Genentech/Roche!**
AI Summary
AC Immune SA announced on January 22, 2024, the termination of two research collaboration and license agreements with Genentech, Inc. and F-Hoffman La-Roche Ltd, originally dated November 6, 2006, and June 15, 2012. As a result, AC Immune will regain all global rights to its Alzheimer's drug candidates, crenezumab and semorinemab. This matters to investors because AC Immune now has full control over the future development and potential commercialization of these two assets, which could lead to new partnerships or direct development, impacting future revenue streams and stock value.
Why It Matters
AC Immune now has complete control over two key Alzheimer's drug candidates, crenezumab and semorinemab, which could lead to new development strategies or partnerships, potentially increasing their value.
Risk Assessment
Risk Level: medium — While regaining rights offers upside, it also means AC Immune bears full development costs and risks for crenezumab and semorinemab without a partner.
Analyst Insight
Investors should monitor AC Immune's upcoming announcements for new development plans or partnerships for crenezumab and semorinemab, as these will dictate the future value of these regained assets.
Key Players & Entities
- AC Immune SA (company) — the registrant regaining drug rights
- Genentech, Inc. (company) — former collaboration partner
- F-Hoffman La-Roche Ltd (company) — former collaboration partner
- Andrea Pfeifer (person) — Chief Executive Officer of AC Immune SA
- Christopher Roberts (person) — Chief Financial Officer of AC Immune SA
Forward-Looking Statements
- AC Immune will seek new partnerships for crenezumab and semorinemab. (AC Immune SA) — medium confidence, target: Q3 2024
- AC Immune's R&D expenses will increase due to taking on full development costs for crenezumab and semorinemab. (AC Immune SA) — high confidence, target: Q4 2024
FAQ
What specific agreements were terminated by AC Immune SA?
AC Immune SA terminated the Research Collaboration and License Agreement dated November 6, 2006, with Genentech, Inc., and the Research Collaboration and License Agreement dated June 15, 2012, with Genentech, Inc. and F-Hoffman La-Roche Ltd.
What assets did AC Immune SA regain global rights to following the termination of these agreements?
Following the termination of these two agreements, AC Immune SA regained all global rights to crenezumab and semorinemab.
When was this termination announced by AC Immune SA?
AC Immune SA issued a press release announcing the termination of the agreements on January 22, 2024.
Who signed the 6-K report on behalf of AC Immune SA?
The 6-K report was signed by Andrea Pfeifer, Chief Executive Officer, and Christopher Roberts, Chief Financial Officer, of AC Immune SA.
What is the significance of Exhibit 99.1 in this 6-K filing?
Exhibit 99.1 is a copy of the press release dated January 22, 2024, announcing the termination of the collaboration agreements, and is attached to this Report on Form 6-K.
Filing Stats: 327 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-01-22 07:53:22
Filing Documents
- dp205552_6k.htm (6-K) — 10KB
- dp205552_ex9901.htm (EX-99.1) — 16KB
- image_001.jpg (GRAPHIC) — 2KB
- image_002.jpg (GRAPHIC) — 2KB
- 0000950103-24-000942.txt ( ) — 34KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On January 22, 2024, AC Immune SA (the “Company”) issued a press release announcing the termination of the Research Collaboration and License Agreement dated November 6, 2006, by and between the Company and Genentech, Inc., and the Research Collaboration and License Agreement dated June 15, 2012, by and among the Company, Genentech, Inc. and F-Hoffman La-Roche Ltd. Following the termination of these two agreements, the Company will regain all global rights to crenezumab and semorinemab. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K. This Report on Form 6-K (other than Exhibit 99.1 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333- 255576, File No. 333-227016 and File No. 333-249655) and Form S-8 (File No. 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Number Description 99.1 Press Release, dated January 22, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AC IMMUNE SA By: /s/ Andrea Pfeifer Name: Andrea Pfeifer Title: Chief Executive Officer By: /s/ Christopher Roberts Name: Christopher Roberts Title: Chief Financial Officer Date: January 22, 2024